|
Amgen to acquire Otezla® for $13.4 billion in cash
|
26 August 2019 |
|
Amgen and Allergan announce positive top-line results from comparative clinical study of ABP 798, biosimilar candidate to Rituxan® (rituximab)
|
22 August 2019 |
|
Amgen and Allergan's MVASI™ (bevacizumab-awwb) and KANJINTI™ (trastuzumab-anns) now available in the United States
|
23 July 2019 |
|
FDA approves Amgen and Allergan's KANJINTITM (trastuzumab-anns), a biosimilar to Herceptin® (trastuzumab)
|
17 June 2019 |
|
Amgen joins with community oncology networks for new research collaboration
|
28 May 2019 |
|
Amgen and Syapse enter precision medicine collaboration in oncology
|
06 May 2019 |
|
Amgen ignites a social fitness movement to support the fight against heart disease and cancer
|
02 May 2019 |
|
EVENITY™ (romosozumab-aqqg) now available in the United States for the treatment of osteoporosis in postmenopausal women at high risk for fracture
|
16 April 2019 |
|
FDA approves EVENITY™ (romosozumab-aqqg) for the treatment of osteoporosis in postmenopausal women at high risk for fracture
|
12 April 2019 |
|
Jury upholds Amgen's patents on Repatha® (evolocumab)
|
27 February 2019 |
|
Amgen, Cytokinetics and Servier announce start of METEORIC-HF, the second Phase 3 clinical trial of omecamtiv mecarbil in patients with heart failure
|
21 February 2019 |
|
Amgen receives NMPA approval for Repatha® (evolocumab) In China to reduce the risk of cardiovascular events
|
28 January 2019 |
|
Amgen and UCB receive positive vote from FDA Advisory Committee in favor of approval for EVENITY™ (romosozumab)
|
17 January 2019 |
|
EVENITY™ (romosozumab) receives approval in Japan for the treatment of osteoporosis in patients at high risk of fracture
|
10 January 2019 |
|
Amgen Golden Tickets provide startup companies with free lab space to further advance innovative science and technology
|
18 December 2018 |
|
Amgen contributes $2 million to groundbreaking program providing cancer patients of all backgrounds access to U.S. clinical trials
|
11 December 2018 |
|
Amgen Foundation deepens commitment to aspiring scientists worldwide by expanding Amgen Scholars Program
|
01 November 2018 |
|
Amgen invests £50 million ($66 Million) in Oxford Nanopore Technologies
|
19 October 2018 |
|
Amgen launches AMGEVITATM (biosimilar adalimumab) in markets across Europe
|
17 October 2018 |
|
World's largest Alzheimer's survey reveals most adults believe a cure will be developed in their lifetime
|
18 September 2018 |